CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Eplerenone

依普利酮 杂质对照品Eplerenone Impurities

EP28 个杂质条目28 impurity entries

本页汇总 依普利酮 的 28 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 28 impurity reference standards of Eplerenone with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 依普利酮(Eplerenone)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA validated stability-indicating ultra performance liquid chromatography method for the determination of potential process-related impurities in eplerenone
    Journal of separation science · 2016 · Du M et al.  ·  PMID 27256957  ·  DOI
  2. 杂质研究Impurity studiesProcess-related impurities of eplerenone: determination and characterisation by HPLC methods and Raman spectroscopy
    Journal of pharmaceutical and biomedical analysis · 2018 · Filip K et al.  ·  PMID 30048894  ·  DOI
  3. 杂质研究Impurity studiesDevelopment and validation of stability indicating RP-HPLC method for the simultaneous estimation of dapagliflozin and eplerenone in bulk and synthetic mixture
    BMC chemistry · 2026 · Tandel P, Mehta H  ·  PMID 42010702  ·  DOI
  4. 分析方法Analytical MethodsA validated SPE-LC-MS/MS assay for Eplerenone and its hydrolyzed metabolite in human urine
    Journal of pharmaceutical and biomedical analysis · 2003 · Zhang JY et al.  ·  PMID 12560054  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisA new approach to the furan degradation problem involving ozonolysis of the trans-enedione and its use in a cost-effective synthesis of eplerenone
    Organic letters · 2006 · Pearlman BA et al.  ·  PMID 16671794  ·  DOI

依普利酮 —— 原料药与杂质对照品Eplerenone — drug substance & impurities

共 29 个条目(含原料药本体)29 items incl. the drug substance
Eplerenone structure
EP原料药 APIAPI
依普利酮Eplerenone
Eplerenone
CAS No.107724-20-9
Chemical FormulaC24H30O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 6 (Eplerenone EP Impurity A) structure
EPA
依普利酮杂质6 (依普利酮EP杂质A)Eplerenone Impurity 6 (Eplerenone EP Impurity A)
Eplerenone Impurity 6 (Eplerenone EP Impurity A)
CAS No.209253-67-8
Chemical FormulaC23H28O5
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 4 (Eplerenone EP Impurity B) structure
EPB
依普利酮杂质4(依普利酮EP杂质B)Eplerenone Impurity 4 (Eplerenone EP Impurity B)
Eplerenone Impurity 4 (Eplerenone EP Impurity B)
CAS No.192704-82-8
Chemical FormulaC24H30O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 1(Eplerenone EP Impurity C) structure
EPC
依普利酮杂质1(依普利酮EP杂质C)Eplerenone Impurity 1(Eplerenone EP Impurity C)
Eplerenone Impurity 1(Eplerenone EP Impurity C)
CAS No.95716-70-4
Chemical FormulaC24H30O5
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 15 (Eplerenone EP Impurity D) structure
EPD
依普利酮杂质15 (依普利酮EP杂质D)Eplerenone Impurity 15 (Eplerenone EP Impurity D)
Eplerenone Impurity 15 (Eplerenone EP Impurity D)
CAS No.209253-82-7
Chemical FormulaC23H28O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 2(Eplerenone EP Impurity E) structure
EPE
依普利酮杂质2(依普利酮EP杂质E)Eplerenone Impurity 2(Eplerenone EP Impurity E)
Eplerenone Impurity 2(Eplerenone EP Impurity E)
CAS No.209253-81-6
Chemical FormulaC24H30O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 13 Monomer (Eplerenone EP Impurity F) structure
EPF
依普利酮杂质13 单体 (依普利酮EP杂质F)Eplerenone Impurity 13 Monomer (Eplerenone EP Impurity F)
Eplerenone Impurity 13 Monomer (Eplerenone EP Impurity F)
CAS No.579484-30-3
Chemical FormulaC24H32O7
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 13 Potassium Salt (Eplerenone EP Impurity F Potassium Salt) structure
EPF
依普利酮杂质13 钾盐 (依普利酮EP杂质F 钾盐)Eplerenone Impurity 13 Potassium Salt (Eplerenone EP Impurity F Potassium Salt)
Eplerenone Impurity 13 Potassium Salt (Eplerenone EP Impurity F Potassium Salt)
CAS No.95716-98-6
Chemical FormulaC24H31O7-·K+
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 16(Eplerenone EP Impurity G) structure
EPG
依普利酮杂质16(依普利酮EP杂质G)Eplerenone Impurity 16(Eplerenone EP Impurity G)
Eplerenone Impurity 16(Eplerenone EP Impurity G)
CAS No.41020-65-9
Chemical FormulaC24H32O5
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 3 structure
3
依普利酮杂质3Eplerenone Impurity 3
Eplerenone Impurity 3
CAS No.209253-73-6
Chemical FormulaC24H30O7
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 5 structure
5
依普利酮杂质5Eplerenone Impurity 5
Eplerenone Impurity 5
CAS No.192704-56-6
Chemical FormulaC24H32O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 7 structure
7
依普利酮杂质7Eplerenone Impurity 7
Eplerenone Impurity 7
CAS No.192704-70-4
Chemical FormulaC24H30O5
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 8 structure
8
依普利酮杂质8Eplerenone Impurity 8
Eplerenone Impurity 8
CAS No.192704-54-4
Chemical FormulaC24H29NO5
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 9 structure
9
依普利酮杂质9Eplerenone Impurity 9
Eplerenone Impurity 9
CAS No.209253-72-5
Chemical FormulaC23H30O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 11 structure
11
依普利酮杂质11Eplerenone Impurity 11
Eplerenone Impurity 11
CAS No.209253-80-5
Chemical FormulaC24H30O7
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 14 structure
14
依普利酮杂质14Eplerenone Impurity 14
Eplerenone Impurity 14
CAS No.1621954-05-9
Chemical FormulaC23H30O7
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 22 structure
22
依普利酮杂质22Eplerenone Impurity 22
Eplerenone Impurity 22
CAS No.2304869-74-5
Chemical FormulaC24H30O5
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 23 structure
23
依普利酮杂质23Eplerenone Impurity 23
Eplerenone Impurity 23
CAS No.2304869-71-2
Chemical FormulaC24H32O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 24 structure
24
依普利酮杂质24Eplerenone Impurity 24
Eplerenone Impurity 24
CAS No.192569-17-8
Chemical FormulaC22H28O4
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 25 structure
25
依普利酮杂质25Eplerenone Impurity 25
Eplerenone Impurity 25
CAS No.192704-58-8
Chemical FormulaC25H34O8S
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 27 structure
27
依普利酮杂质27Eplerenone Impurity 27
Eplerenone Impurity 27
CAS No.209253-91-8
Chemical FormulaC23H30O6S
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 30 structure
30
依普利酮杂质30Eplerenone Impurity 30
Eplerenone Impurity 30
CAS No.209253-70-3
Chemical FormulaC24H30O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 37 structure
37
依普利酮杂质37Eplerenone Impurity 37
Eplerenone Impurity 37
CAS No.95716-71-5
Chemical FormulaC22H26O3
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 44 structure
44
依普利酮杂质44Eplerenone Impurity 44
Eplerenone Impurity 44
CAS No.910107-80-1
Chemical FormulaC23H27NO4
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 47 structure
47
依普利酮杂质47Eplerenone Impurity 47
Eplerenone Impurity 47
CAS No.95716-74-8
Chemical FormulaC23H28O5
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 50 (17β-Eplerenone) structure
50
依普利酮杂质50 (17β-依普利酮)Eplerenone Impurity 50 (17β-Eplerenone)
Eplerenone Impurity 50 (17β-Eplerenone)
CAS No.395665-48-2
Chemical FormulaC24H30O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 55 structure
55
依普利酮杂质55Eplerenone Impurity 55
Eplerenone Impurity 55
CAS No.209253-58-7
Chemical FormulaC23H29NO4
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 56 structure
56
依普利酮杂质56Eplerenone Impurity 56
Eplerenone Impurity 56
CAS No.209253-48-5
Chemical FormulaC24H32O6
Purity>95%询价On request
10mg25mg50mg100mg
Eplerenone Impurity 63 structure
63
依普利酮杂质63Eplerenone Impurity 63
Eplerenone Impurity 63
CAS No.1061243-14-8
Chemical FormulaC25H32O9S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

依普利酮 —— 研究文献与合成路线Eplerenone — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 依普利酮 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Eplerenone. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Degradation Pathway for Eplerenone by Validated Stability Indicating UP-LC Method
    Sudhakar Babu K, Madireddy V, Indukuri VS · ISRN pharmaceutics · 2012 · 被引 2cited 2
  2. A validated stability-indicating ultra performance liquid chromatography method for the determination of potential process-related impurities in eplerenone
    Du M, Pan C, Chen J, et al. · Journal of separation science · 2016 · 被引 4cited 4
  3. Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of dapagliflozin and eplerenone in bulk and synthetic mixture
    Tandel P, Mehta H · BMC chemistry · 2026
  4. A new approach to the furan degradation problem involving ozonolysis of the trans-enedione and its use in a cost-effective synthesis of eplerenone
    Pearlman BA, Padilla AG, Hach JT, et al. · Organic letters · 2006 · 被引 11cited 11
  5. Synthesis and Physicochemical Characterization of the Process-Related Impurities of Eplerenone, an Antihypertensive Drug
    Dams I, Białońska A, Cmoch P, et al. · Molecules (Basel, Switzerland) · 2017 · 被引 4cited 4
  6. Process-related impurities of eplerenone: determination and characterisation by HPLC methods and Raman spectroscopy
    Filip K, Łaszcz M, Leś A, et al. · Journal of pharmaceutical and biomedical analysis · 2018 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. Method for preparing eplerenone
    DINGJUN CHU, XIANGXIAN HONG · 公开号 CN101863951CN101863951 · 2010
  2. PREPARATION METHOD FOR EPLERENONE
    CHU DINGJUN, HONG XIANGXIAN · 公开号 WO2010118560WO2010118560 · 2010
  3. Process to Prepare Eplerenone
    PEARLMAN BRUCE A, PADILLA AMPHLETT G, HAVENS JEFFREY L, MACKEY SONJA S, et al. · 公开号 US2007117780US2007117780 · 2007
  4. Processes to prepare eplerenone
    PEARLMAN BRUCE A, PADILLA AMPHLETT G, HAVENS JEFFREY L, MACKEY SONJA S, et al. · 公开号 US2007129332US2007129332 · 2007
  5. Process to Prepare Eplerenone
    PEARLMAN BRUCE A, PADILLA AMPHLETT G, HAVENS JEFFREY L, MACKEY SONJA S, et al. · 公开号 US2007100140US2007100140 · 2007

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

依普利酮 杂质谱研究要点Eplerenone — impurity profiling notes

下面这些是拿到 依普利酮 的 29 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 29 impurity entries for Eplerenone, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances